True Wealth Design’s Nuvectis Pharma NVCT Stock Holding History

True Wealth Design’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$85	Hold	4	–	–	﹤0.01%	2462
2026 Q2	$74	Buy	+4	New	+$45	﹤0.01%	2570

Other funds holding NVCT

Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return

J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

True Wealth Design's NVCT Position: Q3 2026 in Review

True Wealth Design held its Nuvectis Pharma (NVCT) position steady in Q3 2026 at 4 shares worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #2462.

True Wealth Design first reported a position in NVCT in Q2 2026 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.

True Wealth Design held 4 shares of Nuvectis Pharma worth $85 as of Q3 2026.
True Wealth Design left its Nuvectis Pharma share count unchanged in Q3 2026.
Nuvectis Pharma made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #2462 holding.
True Wealth Design first reported a position in Nuvectis Pharma in Q2 2026 and has held it in 2 quarters since.
9 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.